SHARES in drug maker GlaxoSmithKline rose yesterday after a rival announced that sales of its bird flu drug had more than doubled.
Swiss firm Roche said sales of Tamiflu, which is seen as the best treatment for bird flu, soared to £122m in its third quarter. A number of countries, including the UK, have been stockpiling the anti-viral drug ahead of a possible pandemic.
The increased Tamiflu sales helped Roche to report a 17 per cent rise in group revenues in the three months to the end of September.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article